Cassar J, Ghatei M A, Sarson D L, Joplin G F, Mashiter K, Bloom S R
Clin Endocrinol (Oxf). 1983 Jan;18(1):95-102. doi: 10.1111/j.1365-2265.1983.tb03190.x.
We have performed oral glucose tolerance tests (OGTT) in nine patients with prolactinomas, eight patients with active acromegaly, five patients with acromegaly in remission and nine normal controls, and measured blood glucose, plasma insulin, pancreatic glucagon, enteroglucagon, gastric inhibitory polypeptide (GIP) and GH during the test. Patients with prolactinomas and with active acromegaly were hyperinsulinaemic and five of the nine patients with prolactinomas had impaired glucose tolerance, with blood glucose levels that were significantly higher than the normal controls. Prolactinoma patients had higher GIP levels than those with active acromegaly and both showed a failure of suppression of pancreatic glucagon. Of particular interest was the finding that enteroglucagon, a putative gut growth factor, was low in active acromegaly when compared with acromegaly in remission, but similar to normal in the rest of the patients.
我们对9例催乳素瘤患者、8例活动期肢端肥大症患者、5例缓解期肢端肥大症患者和9名正常对照者进行了口服葡萄糖耐量试验（OGTT），并在试验期间测量了血糖、血浆胰岛素、胰高血糖素、肠高血糖素、胃抑制性多肽（GIP）和生长激素（GH）。催乳素瘤患者和活动期肢端肥大症患者存在高胰岛素血症，9例催乳素瘤患者中有5例糖耐量受损，血糖水平显著高于正常对照者。催乳素瘤患者的GIP水平高于活动期肢端肥大症患者，两者均表现出胰高血糖素抑制功能障碍。特别有趣的是，与缓解期肢端肥大症相比，活动期肢端肥大症患者体内一种假定的肠道生长因子——肠高血糖素水平较低，但在其他患者中与正常水平相似。
